Dr. John Cashman
“A pessimist sees the difficulty in every opportunity; an optimist sees the opportunity in every difficulty.” Winston Churchill
John R. Cashman. Ph.D., President and Founder of the Human BioMolecular Research Institute, has more than 23 years experience in biomedical research as a researcher, consultant, entrepreneur or administrator. In 1997, he founded the Human BioMolecular Research Institute, a non-profit research institute dedicated to performing fundamental and applied research to address important human diseases of the central nervous system. Previously, he was Senior Scientist at the Seattle Biomedical Research Institute and prior to that, he was Associate Director for the IGEN Research Institute in Seattle, Washington. In 1984, he was appointed Assistant Professor of Chemistry and Pharmaceutical Chemistry at the University of California, San Francisco. He completed a postdoctoral fellow in the Department of Chemistry at Harvard University in Cambridge, Massachusetts with Professor E.J. Corey (1982-1984). In 1990, Professor Corey received the Nobel Prize. Dr. Cashman received his Masters and doctorate degrees in Medicinal Chemistry from the University of Kansas, Lawrence, Kansas (1982). Prior to graduate school, he obtained bachelor degrees in chemistry and biology at the College of Creative Studies, University of California, Santa Barbara (1977). Dr. Cashman was a University of California Presidents Undergraduate Researcher (1974-1976), received a Sigma Xi Undergraduate Research fellowship (1975), was a PEW Scholar Nominee at the University of California, San Francisco (1986), received a March of Dimes Basil O’Connor Research Award (1986), was appointed Technical Advisor, San Francisco Estuary Project (1990) and was elected Fellow of the American Association for the Advancement of Science in 1996. In 1991, Dr. Cashman was appointed to the Editorial Advisory Board, Chemical Research in Toxicology and in 1999 he was appointed to the Editorial Advisory Board of Current Drug Metabolism. Dr. Cashman is the author of over 150 research articles or book chapters and 6 patents in the area of drug discovery and evaluation. He is extensively consulted by biotechnology, pharmaceutical industry and government in various areas of human drug development, drug safety evaluation, medicinal chemistry, pharmacogenetics and biochemical toxicology. Dr. Cashman is on the Board of Directors of three biotechnology companies.
October 31st, 2013
01: Winning By Not Losing
When it comes to investing and building wealth, the definition of winning is more times than not all about not losing. Over the last 13 years we’ve witnessed 2 major stock market crashes, the tech bubble and the great crash that began the great recession. If the average loss of those crashes from peak to trough was about 50%, what kind of return would it take to make back your money? Hint: the answer is not 50%
02: Fair Weather Investing Strategy
Some pie chart brokers might tell you the key to financial success is staying in for the long run and riding out the tough times... which has not worked for most investors over the last 13 years, but in a perfect world, if possible, we would all choose to participate only when the market is rising and not when it’s falling. Could something like this actually exist already?
03: Halfway Between a University and a Biotech Company
Brian welcomes the President and Founder of the Human BioMolecular Research Institute, Dr. John Cashman, to the show. Dr. Cashman and his team are improving the lives of other people by researching and discovering breakthroughs towards the cure of some of society’s worst diseases. Dr. Cashman describes HBRI as a mix between a University and a biotech company, and he talks about their goals of each sector. Dr. Cashman gives a lesson on the difference between small molecules and big molecules.
04: The Future Innovation of Research
Dr. John Cashman, President and Founder of the Human BioMolecular Research Institute, discusses one of HBRI’s current projects, an exciting program in cancer research, developing a small molecule that will cure a wide variety of cancers! With 25% of PHD’s in the pharmaceutical industry coming from southern California, Dr. Cashman talks about what he considers to be one of the most rewarding things they do at HBRI, their summer internship programs, giving young, aspiring scientists headstarts in their college and graduate careers.